Lexaria Awards Contract For Third GLP-1 Human Pilot Study

AccesswireMay 23 22:53

Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study

KELOWNA, BC / ACCESSWIRE / May 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot stu

AccesswireMay 8 21:10

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance

KELOWNA, BC / ACCESSWIRE / April 30, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has entered in

AccesswireMay 1 03:40

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Human Pilot Study #2 (GLP-1-H24-2) Approved KELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug de

AccesswireApr 16 21:10

Lexaria Awarded New Patents

Lexaria receives new patents in the fields of epilepsy and anti-viral agentsKELOWNA, BC / ACCESSWIRE / April 2, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria")

AccesswireApr 2 21:00

Lexaria to Present at The LD Micro Invitational XIV

Yahoo FinanceMar 21 21:20